51
|
Smyrniotis CJ, Barbour SR, Xia Z, Hixon MS, Holman TR. ATP allosterically activates the human 5-lipoxygenase molecular mechanism of arachidonic acid and 5(S)-hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic acid. Biochemistry 2014; 53:4407-19. [PMID: 24893149 PMCID: PMC4215895 DOI: 10.1021/bi401621d] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
5-Lipoxygenase
(5-LOX) reacts with arachidonic acid (AA) to first
generate 5(S)-hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic
acid [5(S)-HpETE] and then an epoxide from 5(S)-HpETE to form leukotriene A4, from a single
polyunsaturated fatty acid. This work investigates the kinetic mechanism
of these two processes and the role of ATP in their activation. Specifically,
it was determined that epoxidation of 5(S)-HpETE
(dehydration of the hydroperoxide) has a rate of substrate capture
(Vmax/Km)
significantly lower than that of AA hydroperoxidation (oxidation of
AA to form the hydroperoxide); however, hyperbolic kinetic parameters
for ATP activation indicate a similar activation for AA and 5(S)-HpETE. Solvent isotope effect results for both hydroperoxidation
and epoxidation indicate that a specific step in its molecular mechanism
is changed, possibly because of a lowering of the dependence of the
rate-limiting step on hydrogen atom abstraction and an increase in
the dependency on hydrogen bond rearrangement. Therefore, changes
in ATP concentration in the cell could affect the production of 5-LOX
products, such as leukotrienes and lipoxins, and thus have wide implications
for the regulation of cellular inflammation.
Collapse
Affiliation(s)
- Christopher J Smyrniotis
- Department of Chemistry and Biochemistry, University of California , Santa Cruz, California 95064, United States
| | | | | | | | | |
Collapse
|
52
|
Gehrmann U, Näslund TI, Hiltbrunner S, Larssen P, Gabrielsson S. Harnessing the exosome-induced immune response for cancer immunotherapy. Semin Cancer Biol 2014; 28:58-67. [PMID: 24859748 DOI: 10.1016/j.semcancer.2014.05.003] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 05/08/2014] [Indexed: 12/14/2022]
Abstract
In recent years exosomes have emerged as potent stimulators of immune responses and as agents for cancer therapy. Exosomes can carry a broad variety of immunostimulatory molecules depending on the cell of origin and in vitro culture conditions. Dendritic cell-derived exosomes (dexosomes) have been shown to carry NK cell activating ligands and can be loaded with antigen to activate invariant NKT cells and to induce antigen-specific T and B cell responses. Dexosomes have been investigated as therapeutic agents against cancer in two phase I clinical trials, with a phase II clinical trial currently ongoing. Dexosomes were well tolerated but therapeutic success and immune activation were limited. Several reports suggest that multiple factors need to be considered in order to improve exosomal immunogenicity for cancer immunotherapy. These include antigen-loading strategies, exosome composition and exosomal trafficking in vivo. Hence, a better understanding of how to engineer and deliver exosomes to specific cells is crucial to generate strong immune responses and to improve the immunotherapeutic potential of exosomes.
Collapse
Affiliation(s)
- Ulf Gehrmann
- Translational Immunology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
| | - Tanja I Näslund
- Translational Immunology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
| | - Stefanie Hiltbrunner
- Translational Immunology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
| | - Pia Larssen
- Translational Immunology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
| | - Susanne Gabrielsson
- Translational Immunology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
53
|
Corriveau S, Rousseau É, Blouin S, Pasquier JC. Leukotriene receptor antagonist as a novel tocolytic in an in vitro model of human uterine contractility. Eur J Obstet Gynecol Reprod Biol 2014; 177:77-83. [PMID: 24735655 DOI: 10.1016/j.ejogrb.2014.02.042] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2013] [Revised: 02/18/2014] [Accepted: 02/26/2014] [Indexed: 10/25/2022]
Abstract
OBJECTIVE This study analyzed the ability of montelukast, a cysteinyl-leukotrienes receptor antagonist and anti-inflammatory agent, to produce a consistent tocolytic effect alone or in combination with nifedipine, a calcium (Ca(2+)) channel blocker currently used in clinical practice. STUDY DESIGN Uterine biopsies were obtained from consenting women undergoing elective cesarean sections at term (n=20). Myometrial microsomal fractions were analyzed by immunoblotting to quantify relative cysteinyl leukotrienes receptor 1 (CysLTR1) levels. Isometric tension measurements were performed in vitro on human myometrial strips (n=120) in isolated organ baths in order to establish concentration-response curves to montelukast and to quantify changes in Ca(2+) sensitivity on β-escin permeabilized tissues. RESULTS Immunodetection analysis revealed the presence of CysLTR1 receptor in uterine tissues, fetal membranes and placenta. A significant increase in area under the curve (AUC) was quantified following the addition of leukotriene D4 (LTD4) (0.01-0.3 μM), an end-product of the lipoxygenase pathway. Conversely, addition of montelukast produced a significant tocolytic effect by decreasing the frequency and AUC (IC₅₀=1 μM). Moreover, addition of montelukast also resulted in a reduced Ca(2+) sensitivity as compared to control tissues (EC₅₀ values of 654 and 403 nM; p=0.02 at pCa 6), while an additive effect was observed in combination with 0.1 nM nifedipine (p=0.004). CONCLUSION This original study demonstrates the potency of montelukast as a tocolytic agent in an in vitro human uterine model. Montelukast, in combination with nifedipine, could represent a therapeutic approach to reduce inflammation associated with prematurity while facilitating the inhibition of preterm labor.
Collapse
Affiliation(s)
- Stéphanie Corriveau
- Obstetrics and Gynecology, CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada; Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada
| | - Éric Rousseau
- Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada
| | - Simon Blouin
- Obstetrics and Gynecology, CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada
| | - Jean-Charles Pasquier
- Obstetrics and Gynecology, CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
| |
Collapse
|
54
|
Stanke-Labesque F, Pépin JL, Gautier-Veyret E, Lévy P, Bäck M. Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovasc Res 2013; 101:187-93. [DOI: 10.1093/cvr/cvt247] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
55
|
Neels JG. A role for 5-lipoxygenase products in obesity-associated inflammation and insulin resistance. Adipocyte 2013; 2:262-5. [PMID: 24052903 PMCID: PMC3774703 DOI: 10.4161/adip.24835] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2013] [Revised: 04/26/2013] [Accepted: 04/26/2013] [Indexed: 01/20/2023] Open
Abstract
There is a growing amount of evidence that obesity-induced low-grade inflammation is an important causative link between obesity and many of its associated pathologies such as type 2 diabetes and atherosclerosis. In the quest to identify the triggers of obesity-associated inflammation of adipose tissue, our laboratory recently demonstrated that adipocytes can secrete leukotrienes, and that these pro-inflammatory lipid mediators contribute to obesity-associated inflammation and insulin resistance in mice. Together with other recent studies, our recent findings identify an important role for the enzyme 5-lipoxygenase and its products in the induction and resolution of adipose tissue inflammation. Therefore, pharmaceutical approaches that target this enzyme or its products should be considered as novel treatments aimed at preventing or resolving obesity-induced inflammation and its associated pathologies.
Collapse
|
56
|
Maskrey BH, Megson IL, Rossi AG, Whitfield PD. Emerging importance of omega-3 fatty acids in the innate immune response: molecular mechanisms and lipidomic strategies for their analysis. Mol Nutr Food Res 2013; 57:1390-400. [PMID: 23417926 DOI: 10.1002/mnfr.201200723] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 12/12/2012] [Accepted: 12/12/2012] [Indexed: 12/22/2022]
Abstract
The beneficial health properties of dietary omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have long been known and their metabolic dysfunction has been linked to a range of diseases including various inflammatory disorders, cardiovascular diseases, and cancer. However, the molecular mechanisms underlying their health benefits have remained unclear. Recent technological advances in lipidomic analytical strategies have resulted in the discovery of a range of bioactive mediators derived from EPA and DHA that possess potent anti-inflammatory and pro-resolving properties and that may be responsible, at least in part, for the beneficial effects observed. These mediators include resolvins, protectins and maresins, as well as EPA derivatives of classical arachidonic acid derived eicosanoids, such as prostaglandin E3 . The aim of this review is to provide an overview of the biosynthetic pathways and biological properties of these omega-3 mediators, with a particular focus on the emerging importance of the counter-regulatory role of omega-3 and -6 fatty acids in the spatial and temporal regulation of the inflammatory response. It will also provide an insight into a range of lipidomic approaches, which are currently available to analyse these fatty acids and their metabolites in biological matrices.
Collapse
Affiliation(s)
- Benjamin H Maskrey
- Lipidomics Research Facility, Department of Diabetes and Cardiovascular Science, University of the Highlands and Islands, Inverness, UK.
| | | | | | | |
Collapse
|
57
|
Record M, Poirot M, Silvente-Poirot S. Emerging concepts on the role of exosomes in lipid metabolic diseases. Biochimie 2013; 96:67-74. [PMID: 23827857 DOI: 10.1016/j.biochi.2013.06.016] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Accepted: 06/18/2013] [Indexed: 02/06/2023]
Abstract
Dysregulation of lipid metabolism involves cellular communication mediated by cell contacts or exchange of bioactive lipids bound to soluble carriers or to lipoproteins. An increasing field is that of cellular communication mediated by nanovesicles called exosomes. Those vesicles are released from an internal compartment of viable cells, circulate in all biological fluids and can transfer material from cell-to-cells. Involvement of exosome trafficking in the transcellular metabolism of eicosanoids and cholesterol-related diseases including cancer is developed hereafter.
Collapse
Affiliation(s)
- Michel Record
- INSERM-UMR 1037, Cancer Research Center of Toulouse (CRCT), Team «Sterol Metabolism and Therapeutic Innovation in Oncology», BP3028, CHU Purpan, Toulouse F-31300, France; Institut Claudius Regaud, 20-24 Rue du Pont Saint-Pierre, 31052 Toulouse Cedex, France; Université Paul Sabatier, 118 Route de Narbonne, Toulouse, France.
| | | | | |
Collapse
|
58
|
Lone AM, Taskén K. Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol 2013; 4:130. [PMID: 23760108 PMCID: PMC3671288 DOI: 10.3389/fimmu.2013.00130] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 05/17/2013] [Indexed: 01/08/2023] Open
Abstract
Eicosanoids are inflammatory mediators primarily generated by hydrolysis of membrane phospholipids by phospholipase A2 to ω-3 and ω-6 C20 fatty acids that next are converted to leukotrienes (LTs), prostaglandins (PGs), prostacyclins (PCs), and thromboxanes (TXAs). The rate-limiting and tightly regulated lipoxygenases control synthesis of LTs while the equally well-controlled cyclooxygenases 1 and 2 generate prostanoids, including PGs, PCs, and TXAs. While many of the classical signs of inflammation such as redness, swelling, pain, and heat are caused by eicosanoid species with vasoactive, pyretic, and pain-inducing effects locally, some eicosanoids also regulate T cell functions. Here, we will review eicosanoid production in T cell subsets and the inflammatory and immunoregulatory functions of LTs, PGs, PCs, and TXAs in T cells.
Collapse
Affiliation(s)
- Anna Mari Lone
- Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital , Oslo , Norway ; Biotechnology Centre, University of Oslo , Oslo , Norway ; K.G. Jebsen Inflammation Research Centre, University of Oslo , Oslo , Norway
| | | |
Collapse
|
59
|
Cooke M, Di Cónsoli H, Maloberti P, Cornejo Maciel F. Expression and function of OXE receptor, an eicosanoid receptor, in steroidogenic cells. Mol Cell Endocrinol 2013; 371:71-8. [PMID: 23159987 DOI: 10.1016/j.mce.2012.11.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2012] [Revised: 11/05/2012] [Accepted: 11/06/2012] [Indexed: 10/27/2022]
Abstract
Hormonal regulation of steroidogenesis involves arachidonic acid (AA) metabolism through the 5-lipoxygenase pathway. One of the products, 5-hydroperoxy-eicosatetraenoic acid (5-HpETE), acts as a modulator of the activity of the steroidogenic acute regulatory (StAR) protein promoter. Besides, an oxoeicosanoid receptor of the leukotriene receptor family named OXE-R is a membrane protein with high affinity and response to 5-HpETE, among other AA derivatives. The aim of our work was to elucidate whether this receptor may be involved in steroidogenesis. RT-PCR and western blot analysis demonstrated the presence of the mRNA and protein of the receptor in human H295R adrenocortical cells. The treatment of H295R or MA-10 cells (murine Leydig cell line) with 8Br-cAMP together with docosahexaenoic acid (DHA, an antagonist of the receptor) partially reduced StAR induction and steroidogenesis. On the contrary, 5-oxo-ETE - the prototypical agonist, with higher affinity and potency on the receptor - increased cAMP-dependent steroid production, StAR mRNA and protein levels. These results lead us to conclude that AA might modulate StAR induction and steroidogenesis, at least in part, through 5-HpETE production and activation of a membrane receptor, such as the OXE-R.
Collapse
Affiliation(s)
- Mariana Cooke
- INBIOMED - UBA/CONICET, Department of Biochemistry, School of Medicine, University of Buenos Aires, Paraguay 2155, C1121ABG Buenos Aires, Argentina
| | | | | | | |
Collapse
|
60
|
Tootle TL. Genetic insights into the in vivo functions of prostaglandin signaling. Int J Biochem Cell Biol 2013; 45:1629-32. [PMID: 23685076 DOI: 10.1016/j.biocel.2013.05.008] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2013] [Revised: 05/08/2013] [Accepted: 05/09/2013] [Indexed: 01/05/2023]
Abstract
Prostaglandins (PGs) are lipid signals that are produced at their sites of action by cyclooxygenase (COX) enzymes, the targets of non-steroidal anti-inflammatory drugs (NSAIDs), and PG-type specific synthases. Active PGs serve as ligands for G protein-coupled receptors (GPCRs). The functions of PGs have largely been elucidated using pharmacologic, expression-based (synthesis and signaling components), and genetic studies. In this review, we discuss the in vivo roles of PGs in cancer, development, and reproduction that have been characterized using genetic knockout/knockdown and overexpression approaches in mice, zebrafish, and invertebrate model systems, and how pharmacologic inhibition of PG synthesis affects cardiovascular health/disease and cancer incidence and progression.
Collapse
Affiliation(s)
- Tina L Tootle
- Anatomy and Cell Biology Department, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, United States.
| |
Collapse
|
61
|
Canny GO, Lessey BA. The role of lipoxin A4 in endometrial biology and endometriosis. Mucosal Immunol 2013; 6:439-50. [PMID: 23485944 PMCID: PMC4062302 DOI: 10.1038/mi.2013.9] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Lipoxin A4 (LXA4), an endogenous anti-inflammatory and immunomodulatory mediator studied in many disease states, is recently appreciated as a potentially significant player in the endometrium. This eicosanoid, synthesized from arachidonic acid via the action of lipoxygenase enzymes, is likely regulated in endometrial tissue during the menstrual cycle. Recent studies revealed that LXA4 acts as an estrogen receptor agonist in endometrial epithelial cells, antagonizing some estrogen-mediated activities in a manner similar to the weak estrogen estriol, with which it shares structural similarity. LXA4 may also be an anti-inflammatory molecule in the endometrium, though its precise function in various physiological and pathological scenarios remains to be determined. The expression patterns for LXA4 and its receptor in the female reproductive tract suggest a role in pregnancy. The present review provides an oversight of its known and putative roles in the context of immuno-endocrine crosstalk. Endometriosis, a common inflammatory condition and a major cause of infertility and pain, is currently treated by surgery or anti-hormone therapies that are contraceptive and associated with undesirable side effects. LXA4 may represent a potential therapeutic and further research to elucidate its function in endometrial tissue and the peritoneal cavity will undoubtedly provide valuable insights.
Collapse
Affiliation(s)
- GO Canny
- Geneva Foundation for Medical Education and Research, Versoix, Switzerland
| | - BA Lessey
- University of South Carolina School of Medicine—Greenville, Greenville, SC, USA
| |
Collapse
|
62
|
Long EK, Hellberg K, Foncea R, Hertzel AV, Suttles J, Bernlohr DA. Fatty acids induce leukotriene C4 synthesis in macrophages in a fatty acid binding protein-dependent manner. Biochim Biophys Acta Mol Cell Biol Lipids 2013; 1831:1199-207. [PMID: 23583845 DOI: 10.1016/j.bbalip.2013.04.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 04/02/2013] [Accepted: 04/05/2013] [Indexed: 12/30/2022]
Abstract
Obesity results in increased macrophage recruitment to adipose tissue that promotes a chronic low-grade inflammatory state linked to increased fatty acid efflux from adipocytes. Activated macrophages produce a variety of pro-inflammatory lipids such as leukotriene C4 (LTC4) and 5-, 12-, and 15-hydroxyeicosatetraenoic acid (HETE) suggesting the hypothesis that fatty acids may stimulate eicosanoid synthesis. To assess if eicosanoid production increases with obesity, adipose tissue of leptin deficient ob/ob mice was analyzed. In ob/ob mice, LTC4 and 12-HETE levels increased in the visceral (but not subcutaneous) adipose depot while the 5-HETE levels decreased and 15-HETE abundance was unchanged. Since macrophages produce the majority of inflammatory molecules in adipose tissue, treatment of RAW264.7 or primary peritoneal macrophages with free fatty acids led to increased secretion of LTC4 and 5-HETE, but not 12- or 15-HETE. Fatty acid binding proteins (FABPs) facilitate the intracellular trafficking of fatty acids and other hydrophobic ligands and in vitro stabilize the LTC4 precursor leukotriene A4 (LTA4) from non-enzymatic hydrolysis. Consistent with a role for FABPs in LTC4 synthesis, treatment of macrophages with HTS01037, a specific FABP inhibitor, resulted in a marked decrease in both basal and fatty acid-stimulated LTC4 secretion but no change in 5-HETE production or 5-lipoxygenase expression. These results indicate that the products of adipocyte lipolysis may stimulate the 5-lipoxygenase pathway leading to FABP-dependent production of LTC4 and contribute to the insulin resistant state.
Collapse
Affiliation(s)
- Eric K Long
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455 USA
| | | | | | | | | | | |
Collapse
|
63
|
Sharma P, Ryu MH, Basu S, Maltby SA, Yeganeh B, Mutawe MM, Mitchell RW, Halayko AJ. Epithelium-dependent modulation of responsiveness of airways from caveolin-1 knockout mice is mediated through cyclooxygenase-2 and 5-lipoxygenase. Br J Pharmacol 2013; 167:548-60. [PMID: 22551156 DOI: 10.1111/j.1476-5381.2012.02014.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE Acute silencing of caveolin-1 (Cav-1) modulates receptor-mediated contraction of airway smooth muscle. Moreover, COX-2- and 5-lipoxygenase (5-LO)-derived prostaglandin and leukotriene biosynthesis can influence smooth muscle reactivity. COX-2 half-life can be prolonged through association with Cav-1. We suggested that lack of Cav-1 modulated levels of COX-2 which in turn modulated tracheal contraction, when arachidonic acid signalling was disturbed by inhibition of COX-2. EXPERIMENTAL APPROACH Using tracheal rings from Cav-1 knockout (KO) and wild-type mice (B6129SF2/J), we measured isometric contractions to methacholine and used PCR, immunoblotting and immunohistology to monitor expression of relevant proteins. KEY RESULTS Tracheal rings from Cav-1 KO and wild-type mice exhibited similar responses, but the COX-2 inhibitor, indomethacin, increased responses of tracheal rings from Cav-1 KO mice to methacholine. The phospholipase A₂ inhibitor, eicosatetraynoic acid, which inhibits formation of both COX-2 and 5-LO metabolites, had no effect on wild-type or Cav-1 KO tissues. Indomethacin-mediated hyperreactivity was ablated by the LTD₄ receptor antagonist (montelukast) and 5-LO inhibitor (zileuton). The potentiating effect of indomethacin on Cav-1 KO responses to methacholine was blocked by epithelial denudation. Immunoprecipitation showed that COX-2 binds Cav-1 in wild-type lungs. Immunoblotting and qPCR revealed elevated levels of COX-2 and 5-LO protein, but not COX-1, in Cav-1 KO tracheas, a feature that was prevented by removal of the epithelium. CONCLUSION AND IMPLICATIONS The indomethacin-induced hypercontractility observed in Cav-1 KO tracheas was linked to increased expression of COX-2 and 5-LO, which probably enhanced arachidonic acid shunting and generation of pro-contractile leukotrienes when COX-2 was inhibited.
Collapse
Affiliation(s)
- Pawan Sharma
- Department of Physiology, University of Manitoba, Winnipeg, MB, Canada
| | | | | | | | | | | | | | | |
Collapse
|
64
|
Kendall AC, Nicolaou A. Bioactive lipid mediators in skin inflammation and immunity. Prog Lipid Res 2012; 52:141-64. [PMID: 23124022 DOI: 10.1016/j.plipres.2012.10.003] [Citation(s) in RCA: 149] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Revised: 10/15/2012] [Accepted: 10/17/2012] [Indexed: 12/20/2022]
Abstract
The skin is the primary barrier from the outside environment, protecting the host from injury, infectious pathogens, water loss and solar ultraviolet radiation. In this role, it is supported by a highly organized system comprising elements of innate and adaptive immunity, responsive to inflammatory stimuli. The cutaneous immune system is regulated by mediators such as cytokines and bioactive lipids that can initiate rapid immune responses with controlled inflammation, followed by efficient resolution. However, when immune responses are inadequate or mounted against non-infectious agents, these mediators contribute to skin pathologies involving unresolved or chronic inflammation. Skin is characterized by active lipid metabolism and fatty acids play crucial roles both in terms of structural integrity and functionality, in particular when transformed to bioactive mediators. Eicosanoids, endocannabinoids and sphingolipids are such key bioactive lipids, intimately involved in skin biology, inflammation and immunity. We discuss their origins, role and influence over various cells of the epidermis, dermis and cutaneous immune system and examine their function in examples of inflammatory skin conditions. We focus on psoriasis, atopic and contact dermatitis, acne vulgaris, wound healing and photodermatology that demonstrate dysregulation of bioactive lipid metabolism and examine ways of using this insight to inform novel therapeutics.
Collapse
Affiliation(s)
- Alexandra C Kendall
- School of Pharmacy and Centre for Skin Sciences, School of Life Sciences, University of Bradford, Richmond Road, Bradford BD7 1DP, UK
| | | |
Collapse
|
65
|
Gleim S, Stitham J, Tang WH, Martin KA, Hwa J. An eicosanoid-centric view of atherothrombotic risk factors. Cell Mol Life Sci 2012; 69:3361-80. [PMID: 22491820 PMCID: PMC3691514 DOI: 10.1007/s00018-012-0982-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2012] [Revised: 03/22/2012] [Accepted: 03/26/2012] [Indexed: 02/06/2023]
Abstract
Cardiovascular disease is the foremost cause of morbidity and mortality in the Western world. Atherosclerosis followed by thrombosis (atherothrombosis) is the pathological process underlying most myocardial, cerebral, and peripheral vascular events. Atherothrombosis is a complex and heterogeneous inflammatory process that involves interactions between many cell types (including vascular smooth muscle cells, endothelial cells, macrophages, and platelets) and processes (including migration, proliferation, and activation). Despite a wealth of knowledge from many recent studies using knockout mouse and human genetic studies (GWAS and candidate approach) identifying genes and proteins directly involved in these processes, traditional cardiovascular risk factors (hyperlipidemia, hypertension, smoking, diabetes mellitus, sex, and age) remain the most useful predictor of disease. Eicosanoids (20 carbon polyunsaturated fatty acid derivatives of arachidonic acid and other essential fatty acids) are emerging as important regulators of cardiovascular disease processes. Drugs indirectly modulating these signals, including COX-1/COX-2 inhibitors, have proven to play major roles in the atherothrombotic process. However, the complexity of their roles and regulation by opposing eicosanoid signaling, have contributed to the lack of therapies directed at the eicosanoid receptors themselves. This is likely to change, as our understanding of the structure, signaling, and function of the eicosanoid receptors improves. Indeed, a major advance is emerging from the characterization of dysfunctional naturally occurring mutations of the eicosanoid receptors. In light of the proven and continuing importance of risk factors, we have elected to focus on the relationship between eicosanoids and cardiovascular risk factors.
Collapse
Affiliation(s)
- Scott Gleim
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511
| | - Jeremiah Stitham
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511
| | - Wai Ho Tang
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511
| | - Kathleen A. Martin
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511
| | - John Hwa
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511
| |
Collapse
|
66
|
Li L, Zeng HW, Liu F, Zhang JG, Yue RC, Lu WQ, Yuan X, Dai WX, Yuan H, Sun QY, Huang J, Li HL, Li YS, Shan L, Zhang WD. Target Identification and Validation of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate, an Anti-Inflammatory Natural Product. EUR J INFLAMM 2012. [DOI: 10.1177/1721727x1201000306] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
(+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate (HOEC) was isolated from Incarvillea mairei var. granditlora (Wehrhahn) Grierson. The plants of the Incarvillea genus have long been used as folk medicines for the treatment of inflammation-related diseases in China. 5-Lipoxygenase (5-LOX), a key enzyme in the arachidonic acid (AA) cascade, was identified as a potential target of HOEC by a pulldown assay, and then extensively validated by biosensor-based affinity detection, enzyme-based activity assays, cell-based AA metabolite analysis and computer-aided AA network simulation. Further in vivo studies of AA-induced ear oedema, ovalbumin (OVA)-induced lung inflammation and collagen-induced arthritis demonstrated the anti-inflammatory potency and validated the therapeutic target of HOEC. This work revealed that HOEC acted as an anti-inflammatory agent targeting 5-LOX, which not only confirmed the key role of 5-LOX in inflammation but also provided a paradigm for the exploration of natural product mechanisms of action.
Collapse
Affiliation(s)
- L. Li
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
- Department of Pharmacognosy, Shenyang Pharmaceutical University, Shenyang, Liaoning Province, PR China
| | - H-W. Zeng
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - F. Liu
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - J-G. Zhang
- Department of Natural Product Chemistry, School of Pharmacy, Shanghai Jiaotong University, Shanghai, PR China
| | - R-C. Yue
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - W-Q. Lu
- School of Pharmacy, East China University of Science and Technology, Shanghai, PR China
| | - X. Yuan
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - W-X. Dai
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - H. Yuan
- Department of Natural Product Chemistry, School of Pharmacy, Shanghai Jiaotong University, Shanghai, PR China
| | - Q-Y. Sun
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - J. Huang
- School of Pharmacy, East China University of Science and Technology, Shanghai, PR China
| | - H-L. Li
- School of Pharmacy, East China University of Science and Technology, Shanghai, PR China
| | - Y-S. Li
- Department of Pharmacognosy, Shenyang Pharmaceutical University, Shenyang, Liaoning Province, PR China
| | - L. Shan
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
| | - W-D. Zhang
- Department of Natural Product Chemistry, Second Military Medical University, Shanghai, PR China
- Department of Natural Product Chemistry, School of Pharmacy, Shanghai Jiaotong University, Shanghai, PR China
| |
Collapse
|
67
|
Bernstein JM, Lehman H, Lis M, Sands A, Wilding GE, Shultz L, Bankert R, Bobek L. Humanized mouse model used to monitor MUC gene expression in nasal polyps and to preclinically evaluate the efficacy of montelukast in reducing mucus production. Ann Otol Rhinol Laryngol 2012; 121:307-16. [PMID: 22724276 DOI: 10.1177/000348941212100505] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To determine whether MUC gene expression could be down-regulated in nasal polyps by the leukotriene receptor antagonist montelukast, we developed a system in which nondisrupted human nasal polyps could be successfully implanted into severely immunocompromised mice, and in which the histopathology of the original nasal polyp tissue could be preserved for long periods. In addition, the histopathologic changes in the human nasal polyps were carefully examined to determine the origin of the submucosal glands (SMGs) that develop in true nasal polyps found in the anterior third of the nose. METHODS Small, nondisrupted pieces of human nasal polyp tissues were subcutaneously implanted into NOD-scid IL-2rgamma(null) mice. Xenograft-bearing mice were treated with either montelukast or saline solution. Xenografts at 8 to 12 weeks after implantation were examined histologically, and expression of MUC genes 4, 5AC, and 7 was studied in the polyps before implantation and in the 8-week xenograft. Alzet pumps were inserted into the mice, and montelukast (Singulair) was continuously delivered to determine its effect on goblet cell hyperplasia, mucus production, and the enlargement of nasal polyps over an 8-week period. RESULTS The xenografts were maintained in a viable and functional state for up to 3 months and retained a histopathology similar to that of the original tissue, but with a noticeable increase in goblet cell hyperplasia and marked mucus accumulation in the SMGs. MUC4 and MUC5AC were significantly increased in the xenograft 8 weeks after implantation, but MUC7 was significantly decreased compared to the preimplantation polyps. Inasmuch as MUC7 is found exclusively in serous glands, the findings suggest that serous glands are not found in polyps in the anterior third of the nose. The histopathologic findings confirm the original findings of Tos et al suggesting that the SMGs are derived from pinching-off of the epithelium of the enlarging polyp following inflammatory changes. These SMGs have the same epithelium as surface epithelium and consist of multiple goblet cells that secrete periodic acid Schiff stain-positive mucin into the interior of the SMGs. A progressive increase in the volume of the xenografts was observed, with little or no evidence of mouse cell infiltration into the human leukocyte antigen-positive human tissue. An average twofold increase in polyp volume was found 2 months after engraftment. Montelukast did not decrease the growth of the xenograft in the 8-week NOD-scid mice, nor did it affect MUC gene expression. CONCLUSIONS The use of innate and adaptive immunodeficient NOD-scid mice homozygous for targeted mutations in the IL-2 gamma-chain locus NOD-scid IL-2r gamma(null) for establishing engraftment of nondisrupted pieces of human nasal polyp tissues represents a significant advancement in studying chronic inflammation over a long period of time. In the present study, we utilized this humanized mouse model to confirm our prediction that MUC genes 4 and 5AC are highly expressed and significantly increased over those of preimplanted polyps. The overexpression of these 2 MUC genes correlates with both the goblet cell hyperplasia and the excessive mucus production that are found in nasal polyp xenografts. MUC7, which is primarily associated with the submucosa, as opposed to MUC4 and MUC5AC, which are primarily expressed in the epithelium, was significantly decreased in the nasal polyp xenografts. Montelukast had no significant effect on MUC gene expression in the xenografts. In addition to the MUC gene expression patterns, the histology of the xenografts supports the concept that mucinous glands that are characteristic of true nasal polyps are significantly different from those in the mucosa found in the lateral wall of the nose in patients with chronic sinusitis without nasal polyps. The mucinous glands seen in nasal polyps (which appear to be derived from an invagination of hyperplastic epithelial mucosa containing large numbers of goblet cells) are histologically distinct from the seromucinous glands found in the submucosa of hyperplastic middle turbinates. The data presented here establish a humanized mouse model as a viable approach to study nasal polyp growth, to assess the therapeutic efficacy of various drugs in this chronic inflammatory disease, and to contribute to our understanding of the pathogenesis of this disease.
Collapse
Affiliation(s)
- Joel M Bernstein
- Department of Otolaryngology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, USA
| | | | | | | | | | | | | | | |
Collapse
|
68
|
Degousee N, Simpson J, Fazel S, Scholich K, Angoulvant D, Angioni C, Schmidt H, Korotkova M, Stefanski E, Wang XH, Lindsay TF, Ofek E, Pierre S, Butany J, Jakobsson PJ, Keating A, Li RK, Nahrendorf M, Geisslinger G, Backx PH, Rubin BB. Lack of Microsomal Prostaglandin E
2
Synthase-1 in Bone Marrow–Derived Myeloid Cells Impairs Left Ventricular Function and Increases Mortality After Acute Myocardial Infarction. Circulation 2012; 125:2904-13. [DOI: 10.1161/circulationaha.112.099754] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Background—
Microsomal prostaglandin E
2
synthase-1 (mPGES-1), encoded by the
Ptges
gene, catalyzes prostaglandin E
2
biosynthesis and is expressed by leukocytes, cardiac myocytes, and cardiac fibroblasts.
Ptges
−/−
mice develop more left ventricle (LV) dilation, worse LV contractile function, and higher LV end-diastolic pressure than
Ptges
+/+
mice after myocardial infarction. In this study, we define the role of mPGES-1 in bone marrow–derived leukocytes in the recovery of LV function after coronary ligation.
Methods and Results—
Cardiac structure and function in
Ptges
+/+
mice with
Ptges
+/+
bone marrow (
BM
+/+
) and
Ptges
+/+
mice with
Ptges
−/−
BM (
BM
−/−
) were assessed by morphometric analysis, echocardiography, and invasive hemodynamics before and 7 and 28 days after myocardial infarction. Prostaglandin levels and prostaglandin biosynthetic enzyme gene expression were measured by liquid chromatography–tandem mass spectrometry and real-time polymerase chain reaction, immunoblotting, immunohistochemistry, and immunofluorescence microscopy, respectively. After myocardial infarction,
BM
−/−
mice had more LV dilation, worse LV systolic and diastolic function, higher LV end-diastolic pressure, more cardiomyocyte hypertrophy, and higher mortality but similar infarct size and pulmonary edema compared with
BM
+/+
mice.
BM
−/−
mice also had higher levels of COX-1 protein and more leukocytes in the infarct, but not the viable LV, than
BM
+/+
mice. Levels of prostaglandin E
2
were higher in the infarct and viable myocardium of
BM
−/−
mice than in
BM
+/+
mice.
Conclusions—
Lack of mPGES-1 in bone marrow–derived leukocytes negatively regulates COX-1 expression, prostaglandin E
2
biosynthesis, and inflammation in the infarct and leads to impaired LV function, adverse LV remodeling, and decreased survival after acute myocardial infarction.
Collapse
Affiliation(s)
- Norbert Degousee
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Jeremy Simpson
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Shafie Fazel
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Klaus Scholich
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Denis Angoulvant
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Carlo Angioni
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Helmut Schmidt
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Marina Korotkova
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Eva Stefanski
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Xing-Hua Wang
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Thomas F. Lindsay
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Efrat Ofek
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Sandra Pierre
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Jagdish Butany
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Per-Johan Jakobsson
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Armand Keating
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Ren-Ke Li
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Matthias Nahrendorf
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Gerd Geisslinger
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Peter H. Backx
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| | - Barry B. Rubin
- From the Divisions of Vascular Surgery (N.D., E.S., T.F.L., B.B.R.), Cardiac Surgery (S.F., R.-K.L.), Cardiology (P.H.B.), and Pathology (E.O., J.B.), Peter Munk Cardiac Centre, and the Department of Medical Oncology & Hematology (X.-H.W., A.K.), Toronto General Hospital, University Health Network, Toronto, Canada; Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada (J.S., P.H.B.); Institut für Klinische Pharmakologie, Frankfurt am Main, Germany (K.S., C.A., H
| |
Collapse
|
69
|
McCarthy MK, Weinberg JB. Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets. Mediators Inflamm 2012; 2012:236345. [PMID: 22665949 PMCID: PMC3362132 DOI: 10.1155/2012/236345] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Accepted: 03/12/2012] [Indexed: 12/20/2022] Open
Abstract
Viruses are frequent causes of respiratory infection, and viral respiratory infections are significant causes of hospitalization, morbidity, and sometimes mortality in a variety of patient populations. Lung inflammation induced by infection with common respiratory pathogens such as influenza and respiratory syncytial virus is accompanied by increased lung production of prostaglandins and leukotrienes, lipid mediators with a wide range of effects on host immune function. Deficiency or pharmacologic inhibition of prostaglandin and leukotriene production often results in a dampened inflammatory response to acute infection with a respiratory virus. These mediators may, therefore, serve as appealing therapeutic targets for disease caused by respiratory viral infection.
Collapse
Affiliation(s)
- Mary K. McCarthy
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Jason B. Weinberg
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA
- Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI 48109, USA
| |
Collapse
|
70
|
Rozsasi A, Heinemann A, Keck T. Cyclooxygenase 2 and lipoxin A₄ in nasal polyps in cystic fibrosis. Am J Rhinol Allergy 2012; 25:e251-4. [PMID: 22185734 DOI: 10.2500/ajra.2011.25.3726] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
BACKGROUND The etiology of nasal polyps (NPs) and sinusitis in cystic fibrosis (CF) patients is still unknown. This study investigates the presence of cyclooxygenase 2 (COX-2) and lipoxin A(4) (LXA(4)) in epithelial cultures derived from NPs and turbinates in patients with CF and without CF. METHODS NPs and turbinates were evaluated from eight CF patients with obstructing NPs undergoing sinus surgery. NPs and tissue from the hypertrophic inferior turbinate from 14 patients without history of CF undergoing sinus surgery served as control specimens. After tissue culturing, the presence of COX-2 protein and LXA(4) (ELISA) was detected in CF polyps and turbinates and compared with that of the control group. RESULTS COX-2 and LXA(4) were detectable in tissue specimens of all CF patients and control patients. COX-2 was highest in CF polyps, but the difference was not significant compared with CF turbinates or polyps and turbinates of patients not suffering from CF. LXA(4), however, was significantly higher in CF NPs compared with CF turbinate tissue. Compared with NPs of patients not having CF disease, CF polyps showed markedly higher concentrations of LXA(4). CONCLUSION LXA(4) is significantly elevated in CF NPs, whereas COX-2 is only slightly increased. The present data support the concept that LXA(4) plays an important role in CF nasal polyposis. Chronic infection in nasal polyposis and, because of inflammation, induced COX-2 in CF NPs may be related to increased LXA(4). The suspected interaction of COX-2 and LXA(4) needs further investigation.
Collapse
Affiliation(s)
- Ajnacska Rozsasi
- Department of Otorhinolaryngology, Head, Neck, and Facial Plastic Surgery, Elisabethinen Hospital, Academic Hospital of Medical University of Graz, Graz, Austria.
| | | | | |
Collapse
|
71
|
Ueno N, Taketomi Y, Yamamoto K, Hirabayashi T, Kamei D, Kita Y, Shimizu T, Shinzawa K, Tsujimoto Y, Ikeda K, Taguchi R, Murakami M. Analysis of two major intracellular phospholipases A(2) (PLA(2)) in mast cells reveals crucial contribution of cytosolic PLA(2)α, not Ca(2+)-independent PLA(2)β, to lipid mobilization in proximal mast cells and distal fibroblasts. J Biol Chem 2011; 286:37249-63. [PMID: 21880721 DOI: 10.1074/jbc.m111.290312] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Mast cells release a variety of mediators, including arachidonic acid (AA) metabolites, to regulate allergy, inflammation, and host defense, and their differentiation and maturation within extravascular microenvironments depend on the stromal cytokine stem cell factor. Mouse mast cells express two major intracellular phospholipases A(2) (PLA(2)s), namely group IVA cytosolic PLA(2) (cPLA(2)α) and group VIA Ca(2+)-independent PLA(2) (iPLA(2)β), and the role of cPLA(2)α in eicosanoid synthesis by mast cells has been well documented. Lipidomic analyses of mouse bone marrow-derived mast cells (BMMCs) lacking cPLA(2)α (Pla2g4a(-/-)) or iPLA(2)β (Pla2g6(-/-)) revealed that phospholipids with AA were selectively hydrolyzed by cPLA(2)α, not by iPLA(2)β, during FcεRI-mediated activation and even during fibroblast-dependent maturation. Neither FcεRI-dependent effector functions nor maturation-driven phospholipid remodeling was impaired in Pla2g6(-/-) BMMCs. Although BMMCs did not produce prostaglandin E(2) (PGE(2)), the AA released by cPLA(2)α from BMMCs during maturation was converted to PGE(2) by microsomal PGE synthase-1 (mPGES-1) in cocultured fibroblasts, and accordingly, Pla2g4a(-/-) BMMCs promoted microenvironmental PGE(2) synthesis less efficiently than wild-type BMMCs both in vitro and in vivo. Mice deficient in mPGES-1 (Ptges(-/-)) had an augmented local anaphylactic response. These results suggest that cPLA(2)α in mast cells is functionally coupled, through the AA transfer mechanism, with stromal mPGES-1 to provide anti-anaphylactic PGE(2). Although iPLA(2)β is partially responsible for PGE(2) production by macrophages and dendritic cells, it is dispensable for mast cell maturation and function.
Collapse
Affiliation(s)
- Noriko Ueno
- Lipid Metabolism Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 256-8506, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Mullane K. Asthma translational medicine: report card. Biochem Pharmacol 2011; 82:567-85. [PMID: 21741955 DOI: 10.1016/j.bcp.2011.06.038] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Revised: 06/23/2011] [Accepted: 06/24/2011] [Indexed: 01/21/2023]
Abstract
Over the last 30 years, scientific research into asthma has focused almost exclusively on one component of the disorder - airway inflammation - as being the key underlying feature. These studies have provided a remarkably detailed and comprehensive picture of the events following antigen challenge that lead to an influx of T cells and eosinophils in the airways. Indeed, in basic research, even the term "asthma" has become synonymous with a T helper 2 cell-mediated disorder. From this cascade of cellular activation processes and mediators that have been identified it has been possible to pinpoint critical junctures for therapeutic intervention, leading experimentalists to produce therapies that are very effective in decreasing airway inflammation in animal models. Many of these compounds have now completed early Phase 2 "proof-of-concept" clinical trials so the translational success of the basic research model can be evaluated. This commentary discusses clinical results from 39 compounds and biologics acting at 23 different targets, and while 6 of these drugs can be regarded as a qualified success, none benefit the bulk of asthma sufferers. Despite this disappointing rate of success, the same immune paradigm and basic research models, with a few embellishments to incorporate newly identified cells and mediators, continue to drive target identification and drug discovery efforts. It is time to re-evaluate the focus of these efforts.
Collapse
Affiliation(s)
- Kevin Mullane
- Profectus Pharma Consulting, Inc, San Jose, CA 95125, United States.
| |
Collapse
|
73
|
Dumlao DS, Buczynski MW, Norris PC, Harkewicz R, Dennis EA. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim Biophys Acta Mol Cell Biol Lipids 2011; 1811:724-36. [PMID: 21689782 DOI: 10.1016/j.bbalip.2011.06.005] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2011] [Revised: 05/26/2011] [Accepted: 06/02/2011] [Indexed: 01/22/2023]
Abstract
Fatty acid-derived eicosanoids and N-acylethanolamines (NAE) are important bioactive lipid mediators involved in numerous biological processes including cell signaling and disease progression. To facilitate research on these lipid mediators, we have developed a targeted high-throughput mass spectrometric based methodology to monitor and quantitate both eicosanoids and NAEs, and can be analyzed separately or together in series. Each methodology utilizes scheduled multiple reaction monitoring (sMRM) pairs in conjunction with a 25 min reverse-phase HPLC separation. The eicosanoid methodology monitors 141 unique metabolites and quantitative amounts can be determined for over 100 of these metabolites against standards. The analysis covers eicosanoids generated from cycloxygenase, lipoxygenase, cytochrome P450 enzymes, and those generated from non-enzymatic pathways. The NAE analysis monitors 36 metabolites and quantitative amounts can be determined for 33 of these metabolites against standards. The NAE method contains metabolites derived from saturated fatty acids, unsaturated fatty acids, and eicosanoids. The lower limit of detection for eicosanoids ranges from 0.1pg to 1pg, while NAEs ranges from 0.1pg to 1000pg. The rationale and design of the methodology is discussed.
Collapse
Affiliation(s)
- Darren S Dumlao
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA
| | | | | | | | | |
Collapse
|
74
|
Maskrey BH, Megson IL, Whitfield PD, Rossi AG. Mechanisms of Resolution of Inflammation. Arterioscler Thromb Vasc Biol 2011; 31:1001-6. [DOI: 10.1161/atvbaha.110.213850] [Citation(s) in RCA: 120] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The inflammatory response is an integral part of the innate immune mechanism that is triggered in response to a real or perceived threat to tissue homeostasis, with a primary aim of neutralizing infectious agents and initiating repair to damaged tissue. By design, inflammation is a finite process that resolves as soon as the threat of infection abates and sufficient repair to the tissue is complete. Resolution of inflammation involves apoptosis and subsequent clearance of activated inflammatory cells – a tightly regulated event. Chronic inflammation is a characteristic feature in virtually all inflammatory diseases, including atherosclerosis, and it is becoming increasingly clear that derangement of the processes usually involved in resolution of inflammation is an underlying feature of chronic inflammatory conditions. This review will draw on evidence from a range of diseases in which dysregulated inflammation is important, with particular emphasis on cardiovascular disease.
Collapse
Affiliation(s)
- Benjamin H. Maskrey
- From the Lipidomic Research Facility (B.H.M., and P.D.W.) and Free Radical Research Facility (I.L.M.), Highland Diabetes Institute, Centre for Health Science, Inverness, Scotland; and MRC Centre for Inflammation Research (A.G.R.), Queen's Medical Research Institute, University of Edinburgh Medical School, Edinburgh, Scotland
| | - Ian L. Megson
- From the Lipidomic Research Facility (B.H.M., and P.D.W.) and Free Radical Research Facility (I.L.M.), Highland Diabetes Institute, Centre for Health Science, Inverness, Scotland; and MRC Centre for Inflammation Research (A.G.R.), Queen's Medical Research Institute, University of Edinburgh Medical School, Edinburgh, Scotland
| | - Phillip D. Whitfield
- From the Lipidomic Research Facility (B.H.M., and P.D.W.) and Free Radical Research Facility (I.L.M.), Highland Diabetes Institute, Centre for Health Science, Inverness, Scotland; and MRC Centre for Inflammation Research (A.G.R.), Queen's Medical Research Institute, University of Edinburgh Medical School, Edinburgh, Scotland
| | - Adriano G. Rossi
- From the Lipidomic Research Facility (B.H.M., and P.D.W.) and Free Radical Research Facility (I.L.M.), Highland Diabetes Institute, Centre for Health Science, Inverness, Scotland; and MRC Centre for Inflammation Research (A.G.R.), Queen's Medical Research Institute, University of Edinburgh Medical School, Edinburgh, Scotland
| |
Collapse
|
75
|
Nicolaou A, Pilkington SM, Rhodes LE. Ultraviolet-radiation induced skin inflammation: dissecting the role of bioactive lipids. Chem Phys Lipids 2011; 164:535-43. [PMID: 21524643 DOI: 10.1016/j.chemphyslip.2011.04.005] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2011] [Revised: 04/08/2011] [Accepted: 04/10/2011] [Indexed: 11/16/2022]
Abstract
Acute exposure of human skin to the ultraviolet radiation (UVR) in sunlight results in the sunburn response. This is mediated in part by pro-inflammatory eicosanoids and other bioactive lipids, which are in turn produced via mechanisms including UVR-induction of oxidative stress, cell signalling and gene expression. Sunburn is a self-limiting inflammation offering a convenient and accessible system for the study of human cutaneous lipid metabolism. Recent lipidomic applications have revealed that a wider diversity of eicosanoids may be involved in the sunburn response than previously appreciated. This article reviews the effects of UVR on cutaneous lipids and examines the contribution of bioactive lipid mediators in the development of sunburn. Since human skin is an active site of polyunsaturated fatty acid (PUFA) metabolism, and these macronutrients can influence the production of eicosanoids/bioactive lipids, as well as modulate cell signalling, gene expression and oxidative stress, the application of PUFA as potential photoprotective agents is also considered.
Collapse
Affiliation(s)
- Anna Nicolaou
- School of Pharmacy and Centre for Skin Sciences, University of Bradford, Bradford, UK.
| | | | | |
Collapse
|
76
|
Chen H, Manev H. Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice. Neuropharmacology 2010; 60:1058-63. [PMID: 20868701 DOI: 10.1016/j.neuropharm.2010.09.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2010] [Revised: 09/01/2010] [Accepted: 09/07/2010] [Indexed: 10/19/2022]
Abstract
In wild-type (WT) mice, the antibiotic minocycline inhibits development of cocaine-induced locomotor sensitization. Some of the actions of minocycline may involve the 5-lipoxygenase (5-LOX) pathway. We used the model of 5-LOX-deficient mice to investigate whether 5-LOX participates in minocycline's influence on the effects of cocaine. Locomotor sensitization was induced by 4 daily cocaine injections and the phosphorylation status of GluR1 glutamate receptors was assayed in brain samples. Minocycline failed to affect cocaine sensitization in 5-LOX-deficient mice. In these mice, neither cocaine nor minocycline 4-day treatment altered GluR1 phosphorylation. In WT mice in which minocycline inhibited development of cocaine sensitization, a 4-day cocaine treatment increased GluR1 phosphorylation at both Ser831 and Ser845 sites in the frontal cortex but not the striatum; further, this effect was prevented by minocycline. Under basal conditions and in response to a single cocaine injection the levels of GluR1, GluR2, and GluR3 AMPA receptor subunits did not differ between WT and 5-LOX-deficient mice, but the response of GluR1 phosphorylation to a single cocaine injection was greater under the 5-LOX deficiency. Hence, in WT mice GluR1 phosphorylation increased only in the frontal cortex and only at the Ser831 site. In 5-LOX-deficient mice, acute cocaine injection increased both Ser831 and Ser845 phosphorylation both in the frontal cortex and in the striatum. We suggest that in studying minocycline's action on cocaine's effects and/or addiction in humans, it would be important to consider the characterization of the subjects' 5-LOX system. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.
Collapse
Affiliation(s)
- Hu Chen
- The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA
| | | |
Collapse
|
77
|
Platelet - leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk. Mediterr J Hematol Infect Dis 2010; 2:e2010023. [PMID: 21415976 PMCID: PMC3033146 DOI: 10.4084/mjhid.2010.023] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Accepted: 08/08/2010] [Indexed: 11/08/2022] Open
Abstract
The aim of this review is to summarize the contribution of platelets and leukocytes and their interactions in inflammation and blood coagulation and its possible relevance in the pathogenesis of thrombosis. There is some evidence of an association between infection/inflammation and thrombosis. This is likely a bidirectional relationship. The presence of a thrombus may serve as a nidus of infection. Vascular injury indeed promotes platelet and leukocyte activation and thrombus formation and the thrombus and its components facilitate adherence of bacteria to the vessel wall. Alternatively, an infection and the associated inflammation can trigger platelet and leukocyte activation and thrombus formation. In either case platelets and leukocytes co-localize and interact in the area of vascular injury, at sites of inflammation and/or at sites of thrombosis. Following vascular injury, the subendothelial tissue, a thrombogenic surface, becomes available for interaction with these blood cells. Tissue factor, found not only in media and adventitia of the vascular wall, but also on activated platelets and leukocytes, triggers blood coagulation. Vascular-blood cell interactions, mediated by the release of preformed components of the endothelium, is modulated by both cell adhesion and production of soluble stimulatory or inhibitory molecules that alter cell function: adhesion molecules regulate cell-cell contact and facilitate the modulation of biochemical pathways relevant to inflammatory and/or thrombotic processes.
Collapse
|